• Publications
  • Influence
Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis
TLDR
Repeated intranasal stimulation of Toll-like receptor 7 by AZD8848 was safe and produced a sustained reduction in the responsiveness to allergen in allergic rhinitis.
Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis
TLDR
AZD3778 exerts anti-eosinophil and symptom-reducing effects in allergic rhinitis and part of this effect can likely be attributed to CCR3-antagonism.
Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study
TLDR
Repeated administration of AZD8848 activated TLR7 and produced IFN-induced effects was associated with a sustained reduction in allergen responsiveness and reached statistical significance for morning observations.
Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis
TLDR
The rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug roflePonide.
Treatment of idiopathic rhinitis with kinetic oscillations – a multi-centre randomized controlled study
TLDR
The results of the study do not support a convincing treatment effect by KOS on IR, and KOS treatment with high amplitude pressure did not have significant beneficial effects as compared to low amplitude pressure on TVRSS.
HealthSWEDE: costs with sublingual immunotherapy—a Swedish questionnaire study
TLDR
SLIT seems to be a cost-beneficial way to treat seasonal AR with similar consequences to standard of care pharmacological therapy, with presenteeism as main driver.
Symptoms and aspects on eosinophil activity in allergic rhinitis
TLDR
It is demonstrated that repeated individualized allergen challenges can produce symptoms and signs that mimic seasonal disease and that production of the eosinophil chemokine CCL5 is particularly corticosteroid sensitive, suggesting that it may be a valid treatment target.